1
|
Dhanaraj E, Nemmani KVS, Ramarao P. Melatonin inhibits the development of tolerance to U-50,488H analgesia via benzodiazepine?GABAergic mechanisms. Pharmacol Biochem Behav 2004; 79:733-7. [PMID: 15582681 DOI: 10.1016/j.pbb.2004.10.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2004] [Revised: 10/06/2004] [Accepted: 10/06/2004] [Indexed: 11/17/2022]
Abstract
Melatonin, a primary secretory product of pineal gland, is known to produce many of its pharmacological actions via benzodiazepine-gamma-aminobutyric acidA (GABAA)ergic mechanisms. Recently, we showed that benzodiazepine-GABAAergic mechanisms play an important role in U-50,488H (U50) analgesia and its tolerance. Hence, in the present study, the effect of melatonin on U50 analgesia and its tolerance was investigated. Furthermore, the possible role of benzodiazepine-GABAAergic mechanisms in the actions of melatonin on U50 analgesia was investigated. All experiments were performed using the radiant tail-flick test for mice. Melatonin [0.2, 1 and 5 mg/kg, intraperitoneal (i.p.)] neither produced analgesia nor affected the acute U50 (40 mg/kg, i.p.) analgesia. Tolerance to U50 analgesia was induced by administering U50 (40 mg/kg, i.p.) twice daily over 6 days. Treatment with melatonin (1 and 5 mg/kg, i.p) 15 min prior to each dose of U50 inhibited the development of tolerance, whereas a low dose of melatonin (0.2 mg/kg, i.p.) did not. The inhibition of U50 tolerance by melatonin was reversed by the chronic treatment with flumazenil (0.1 mg/kg), a benzodiazepine receptor antagonist and picrotoxin (1 mg/kg), a GABAA-gated chloride channel blocker. Flumazenil and picrotoxin neither affected tail-flick latencies nor altered acute U50 analgesia and its tolerance. Interestingly, chronic 6-day melatonin treatment in a vehicle (U50-naive) group did not alter U50 analgesia measured on day 7. Together, these findings suggest that melatonin interferes with the neural mechanisms involved in the development of tolerance to U50 analgesia. The inhibition of U50 tolerance by melatonin was reversed by flumazenil and picrotoxin treatment, suggesting that benzodiazepine-GABAAergic mechanisms play an important role in the development of tolerance to U50 analgesia and that melatonin inhibits the development of U50 tolerance via benzodiazepine-GABAAergic mechanisms.
Collapse
Affiliation(s)
- Ethiraj Dhanaraj
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Phase-X, S.A.S. Nagar-160 062 (Pb), India
| | | | | |
Collapse
|
2
|
Chen M, Zhou JJ, Kam KWL, Qi JS, Yan WY, Wu S, Wong TM. Roles of KATP channels in delayed cardioprotection and intracellular Ca(2+) in the rat heart as revealed by kappa-opioid receptor stimulation with U50488H. Br J Pharmacol 2004; 140:750-8. [PMID: 14534156 PMCID: PMC1574065 DOI: 10.1038/sj.bjp.0705475] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The effect of preconditioning with U50488 H (UP), a selective kappa-opioid receptor (kappa-OR) agonist, on infarct size and intracellular Ca2+ ([Ca2+]i) in the heart subjected to ischaemic insults were studied and evaluated. U50488 H administered intravenously reduced the infarct size 18-48 h after administration in isolated hearts subjected to regional ischaemia/reperfusion (I/R). The effect was dose dependent. A peak effect was reached at 10 mg x kg-1 U50488 H and at 24 h after administration. The effect of 10 mg x kg-1 U50488 H at 24 h after administration was abolished by nor-binaltorphimine (nor-BNI), a selective kappa-OR antagonist, indicating the effect was kappa-OR mediated. The infarct reducing effect of U50488 H was attenuated when a selective blocker of mitochondrial (5-hydroxydecanoic acid, 5-HD) or sarcolemmal (HRM-1098) ATP-sensitive potassium channel (KATP) was coadministered with U50488 H 24 h before ischaemia or when 5-HD was administered just before ischaemia. U50488 H also attenuated the elevation in [Ca2+]i and reduction in electrically induced [Ca2+]i transient in cardiomyocytes subjected to ischaemic insults. The effects were reversed by blockade of KATP channel, which abolished the protective effect of preconditioning with U50488 H. The results indicated that mitochondrial KATP channel serves as both a trigger and a mediator, while sarcolemmal KATP channel as a trigger only, of delayed cardioprotection of kappa-OR stimulation. The effects of these channels may result from prevention/attenuation of [Ca2+]i overload induced by ischaemic insults.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/antagonists & inhibitors
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/therapeutic use
- Animals
- Calcium/antagonists & inhibitors
- Calcium/metabolism
- Calcium Signaling/drug effects
- Calcium Signaling/physiology
- Coronary Circulation/drug effects
- Coronary Vessels/injuries
- Dose-Response Relationship, Drug
- Heart/drug effects
- Heart/physiology
- Heart Rate/drug effects
- Heart Rate/physiology
- Injections, Intravenous
- Ischemic Preconditioning, Myocardial/methods
- Male
- Myocardial Infarction/complications
- Myocardial Infarction/drug therapy
- Myocardial Reperfusion Injury/complications
- Myocardial Reperfusion Injury/drug therapy
- Myocytes, Cardiac/drug effects
- Myocytes, Cardiac/metabolism
- Naltrexone/analogs & derivatives
- Naltrexone/pharmacology
- Potassium Channel Blockers/metabolism
- Potassium Channel Blockers/pharmacology
- Potassium Channel Blockers/therapeutic use
- Potassium Channels/classification
- Potassium Channels/drug effects
- Potassium Channels/physiology
- Rats/physiology
- Rats, Sprague-Dawley
- Receptors, Opioid, kappa/antagonists & inhibitors
- Receptors, Opioid, kappa/drug effects
- Receptors, Opioid, kappa/metabolism
- Time Factors
Collapse
Affiliation(s)
- Mai Chen
- Department of Physiology, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Jing-Jun Zhou
- Department of Physiology, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Kenneth Wan-Lung Kam
- Department of Physiology, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Jian-Song Qi
- Department of Physiology, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Wing-Yi Yan
- Department of Physiology, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Song Wu
- Department of Physiology, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Tak-Ming Wong
- Department of Physiology, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Author for correspondence:
| |
Collapse
|
3
|
Sternberg WF, Ritchie J, Mogil JS. Qualitative sex differences in kappa-opioid analgesia in mice are dependent on age. Neurosci Lett 2004; 363:178-81. [PMID: 15172110 DOI: 10.1016/j.neulet.2004.04.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2004] [Revised: 03/31/2004] [Accepted: 04/02/2004] [Indexed: 10/26/2022]
Abstract
The effects of aging on sex differences in analgesia from the kappa-opioid agonist, U50,488H (U50), were examined in C57BL/6J mice. U50 analgesia can be blocked by the N-methyl-d-aspartate receptor antagonist, MK-801 (MK), in male rodents and gonadectomized females, but not hormonally intact or estrogen-replaced females, suggesting the existence of alternate neurochemical mediation in females. We now report that MK antagonism of U50 analgesia is age-dependent in females. That is, reproductively senescent females display MK-sensitive U50 analgesia qualitatively similar to that displayed by males or hormonally deprived young females. Age-related reductions in U50 analgesic magnitude were also observed in females. Thus, age and gender are likely to alter the clinical efficacy of analgesic drugs active at kappa-opioid receptors.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/antagonists & inhibitors
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology
- Aging/metabolism
- Analgesics, Non-Narcotic/pharmacology
- Analgesics, Opioid/pharmacology
- Animals
- Central Nervous System/drug effects
- Central Nervous System/metabolism
- Dose-Response Relationship, Drug
- Drug Resistance/physiology
- Estrous Cycle/metabolism
- Excitatory Amino Acid Antagonists/pharmacology
- Female
- Gonadal Steroid Hormones/metabolism
- Menopause/metabolism
- Mice
- Mice, Inbred C57BL
- Pain/drug therapy
- Pain/metabolism
- Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
- Receptors, N-Methyl-D-Aspartate/metabolism
- Receptors, Opioid, kappa/drug effects
- Receptors, Opioid, kappa/metabolism
- Sex Characteristics
Collapse
Affiliation(s)
- Wendy F Sternberg
- Department of Psychology, Haverford College, 370 Lancaster Avenue, Haverford, PA 19041, USA.
| | | | | |
Collapse
|
4
|
Kuzeff RM, Topashka-Ancheva MN, Mecheva RP. Inhibition of (–) -trans-(1S,2S)-U50488 Hydrochloride by Its Enantiomer in White Mice – a Placebo-Controlled, Randomized Study. Complement Med Res 2004; 11:144-9. [PMID: 15249748 DOI: 10.1159/000079443] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Previous studies have been performed to see if toxicity of optically active compounds may be inhibited by potentized preparations of their enantiomers. The present study is based on the hypothesis that the toxic effects of an optical isomer may be counteracted or reversed by the administration of a potentized preparation of one of its stereoisomers and in particular the enantiomer (patent applied for). METHODS The design was prospective, blind, randomized, and placebo-controlled. 210 ICR conventional mice were used. 105 mice were administered a mixture of (+)-U50488 hydrochloride homeopathic potencies prior to and during the experiment, and the other 105 were administered indistinguishable placebo. The first 52 mice were used to establish an LD(50) of intraperitoneally administered (-)-U50488 hydrochloride under the conditions of this experiment. The estimated LD(50) was 25 mg/kg. The remaining 158 mice were then administered this LD(50) of (-)-U50488 HCl intraperitoneally. One mouse from the placebo group was excluded from the analysis because it died immediately after the possibly intravenous injection of (-)-U50488 HCl. RESULTS 67% of homeopathy mice survived compared with 47% of placebo mice. The end point for statistical analysis was the difference in survival between the placebo and homeopathy mice. The analysis was adjusted for mouse weight using a logistic regression (LR) model. The LR treatment odds ratio for survival of treatment mice relative to placebo mice was 2.301 and the LR treatment chi-square was 6.2030 (1 degree of freedom), which has a p-value of 0.0128. Consequently, we reject the null hypothesis of no treatment effect on survival. CONCLUSION We conclude that toxicity of intraperitoneal injection of (-)-U50488 hydrochloride may be inhibited by administration of a mixture of potencies of its enantiomer.
Collapse
Affiliation(s)
- R M Kuzeff
- Graduate School of Integrative Medicine, Swinburne University of Technology, Melbourne, Australia.
| | | | | |
Collapse
|
5
|
Li JG, Zhang F, Jin XL, Liu-Chen LY. Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation. J Pharmacol Exp Ther 2003; 305:531-40. [PMID: 12606694 DOI: 10.1124/jpet.102.045559] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
We previously observed that (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide (U50,488H) promoted internalization and phosphorylation of the FLAG-tagged human kappa opioid receptor (FLAG-hkor) stably expressed in Chinese hamster ovary (CHO) cells. In this study, we compared regulation of the FLAG-hkor expressed in CHO cells by U50,488H, dynorphin A, etorphine, and levorphanol, which were potent full agonists as determined by stimulation of guanosine 5'-O-(3-[(35)S]thio)triphosphate binding. Using fluorescence flow cytometry, we found that dynorphin A(1-17), like U50,488H, promoted internalization of the FLAG-hkor in a time- and dose-dependent manner. The antagonists naloxone and norbinaltorphimine, having no effect on FLAG-hkor internalization, effectively blocked dynorphin A(1-17)- and U50,488H-induced internalization. Interestingly, the full agonists etorphine and levorphanol did not cause internalization of the FLAG-hkor but significantly reduced dynorphin A(1-17)- and U50,488H-induced internalization in a dose-dependent manner. Immunofluorescence staining of FLAG-hkor yielded similar results. Dynorphin A(1-17) and U50,488H enhanced phosphorylation of FLAG-hkor to a greater extent than etorphine, but levorphanol did not increase FLAG-hkor phosphorylation. Etorphine or levorphanol decreased dynorphin- or U50,488H-induced phosphorylation. It is likely that conformations of the hkor required for phosphorylation and initiation of internalization are different from those for activation of G proteins. We also examined whether the four agonists had differential effects on superactivation of adenylate cyclase. Pretreatment with U50,488H, dynorphin A(1-17), or etorphine enhanced forskolin-stimulated adenylate cyclase activity to approximately 200 to 250% of the control, whereas levorphanol pretreatment did not result in significant adenylate cyclase superactivation. Thus, the degree of superactivation caused by an agonist is unrelated to its ability to promote internalization of the hkor.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/antagonists & inhibitors
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/metabolism
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology
- Adenylyl Cyclases/metabolism
- Analgesics, Non-Narcotic/antagonists & inhibitors
- Analgesics, Non-Narcotic/metabolism
- Analgesics, Non-Narcotic/pharmacology
- Analgesics, Opioid/pharmacology
- Animals
- CHO Cells
- Cells, Cultured
- Colforsin/pharmacology
- Cricetinae
- Cyclic AMP/metabolism
- Dynorphins/antagonists & inhibitors
- Dynorphins/metabolism
- Dynorphins/pharmacology
- Etorphine/pharmacology
- Flow Cytometry
- Fluorescent Antibody Technique
- GTP-Binding Proteins/metabolism
- Guanosine 5'-O-(3-Thiotriphosphate)/metabolism
- Humans
- Levorphanol/pharmacology
- Phosphorylation
- Receptors, Opioid, kappa/agonists
Collapse
Affiliation(s)
- Jian-Guo Li
- Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
| | | | | | | |
Collapse
|
6
|
Abstract
Previous studies have shown that the kappa-opioid effects are sensitive to pertussis toxin (PTX) and affected by Ca(2+) fluxes. However, the possible involvement of Ca(2+) channels in PTX-induced inhibition of kappa-opioid effects has not been reported. The effect of intracerebroventricular (i.c.v.) treatment of pertussis toxin (1 microg/rat, PTX) or saline on the kappa-opioid agonist, U-50,488H (U5H) induced tail-flick analgesia and hypothermia in rats was determined. The effect of nimodipine (NIM), a dihydropyridine (DHP)-sensitive Ca(2+) channel blocker (CCB), on PTX-induced modulation of U5H effects was examined. The DHP ligand, [3H]PN200-110 binding was also determined in both PTX and saline treated rats to study the possible involvement of L-type Ca(2+) channels in PTX modulation of kappa-opioid agonist effects. The analgesia and change in colonic temperature were determined using tail-flick analgesiometer and telethermometer, respectively. U5H (40 mg/kg, i.p.) produced significant analgesic and hypothermic responses. PTX treatment significantly (P<0.01) antagonized the analgesic and hypothermic effects of U5H. Acute pretreatment of NIM (1 mg/kg, i.p.) 15 min prior significantly (P<0.01) reversed the PTX-induced antagonism of U5H effects. In the binding study, PTX treatment (72 h before) resulted in a significant (P<0.005) upregulation (+45% vs. saline control) of DHP binding (B(max)) with no change in affinity (K(d)). The results showed significant upregulation of DHP binding in accordance with PTX-induced antagonism of U5H effects and this blockade was reversed by NIM. Thus, present results suggest that U5H-induced analgesia and hypothermia may be mediated through PTX-sensitive transducer G-proteins (G(i/o)) coupled to L-type Ca(2+) channels.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/antagonists & inhibitors
- Analgesics, Non-Narcotic/antagonists & inhibitors
- Animals
- Body Temperature/drug effects
- Calcium Channel Blockers/pharmacology
- Calcium Channels, L-Type/drug effects
- Calcium Channels, L-Type/metabolism
- Calcium Channels, L-Type/physiology
- In Vitro Techniques
- Injections, Intraventricular
- Isradipine/pharmacokinetics
- Male
- Membranes/metabolism
- Nimodipine/pharmacology
- Pain Measurement/drug effects
- Pertussis Toxin/administration & dosage
- Pertussis Toxin/pharmacokinetics
- Pertussis Toxin/pharmacology
- Rats
- Rats, Sprague-Dawley
- Receptors, Opioid, kappa/agonists
Collapse
Affiliation(s)
- Srinivas Gullapalli
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sector 67, Phase -X, S.A.S. Nagar (Mohali)-160 062, Punjab, India
| | | |
Collapse
|
7
|
Rahim RT, Meissler JJ, Cowan A, Rogers TJ, Geller EB, Gaughan J, Adler MW, Eisenstein TK. Administration of mu-, kappa- or delta2-receptor agonists via osmotic minipumps suppresses murine splenic antibody responses. Int Immunopharmacol 2001; 1:2001-9. [PMID: 11606031 DOI: 10.1016/s1567-5769(01)00128-x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Previously, our laboratory has shown that morphine given by implantation of a 75-mg slow-release pellet for 48 h suppresses murine splenic antibody responses to sheep red blood cells (SRBCs) in a plaque-forming cell (PFC) assay. However, the use of slow-release pellets for such studies is limited, as these pellets are only available in fixed doses and similar pellets for kappa and delta agonists have not been developed. In the present study, we investigated the feasibility of administering opioids via Alzet osmotic minipumps to assess their immunomodulatory effects. Groups of mice received minipumps dispensing morphine sulfate, which has primary activity at the mu opioid receptor; U50,488H, which is a kappa-selective agonist; deltorphin II, which is a delta2-selective agonist; or DPDPE, which has greater selectivity for delta1 than delta, receptors. Morphine, U50,488H and deltorphin II were all immunosuppressive, with biphasic dose-response curves exhibiting maximal (approximately 50%) suppression of the PFC response at doses of 0.5 to 2 mg/kg/day 48 h after pump implantation. Further, immunosuppression by morphine sulfate, U50,488H or deltorphin II was blocked by simultaneous implantation of a minipump administering the opioid receptor-selective antagonists CTAP (1 mg/kg/day), nor-binaltorphimine (5 mg/kg/day), or naltriben (3 mg/kg/day), respectively. DPDPE was inactive at doses lower than 10 mg/kg/day. We conclude that osmotic minipumps are a practical and useful way of administering opioids to study their effects on the immune system, and give further evidence that immunosuppression induced in vivo by opioid agonists is mediated not only via mu, but also via kappa and delta2 opioid receptors.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/antagonists & inhibitors
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology
- Analgesics, Opioid/antagonists & inhibitors
- Analgesics, Opioid/pharmacology
- Animals
- Antibody Formation/drug effects
- Depression, Chemical
- Dose-Response Relationship, Drug
- Female
- Immunosuppressive Agents/pharmacology
- Infusion Pumps
- Mice
- Mice, Inbred C3H
- Morphine/antagonists & inhibitors
- Morphine/pharmacology
- Naltrexone/analogs & derivatives
- Naltrexone/pharmacology
- Neuroimmunomodulation
- Oligopeptides/antagonists & inhibitors
- Oligopeptides/pharmacology
- Osmosis
- Peptide Fragments
- Peptides/pharmacology
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/antagonists & inhibitors
- Receptors, Opioid, kappa/agonists
- Receptors, Opioid, kappa/antagonists & inhibitors
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/antagonists & inhibitors
- Somatostatin
- Spleen/drug effects
- Spleen/immunology
Collapse
Affiliation(s)
- R T Rahim
- Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Bileviciute-Ljungar I, Spetea M. Contralateral but not systemic administration of the kappa-opioid agonist U-50,488H induces anti-nociception in acute hindpaw inflammation in rats. Br J Pharmacol 2001; 132:252-8. [PMID: 11156584 PMCID: PMC1572540 DOI: 10.1038/sj.bjp.0703782] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
1. The anti-nociceptive effects of contralateral administration of kappa-opioid agonist U-50,488H were investigated in rats. 2. Inflammation was induced by unilateral injection of 1% carrageenan into the right hindpaw. Prior to carrageenan injection, U-50,488H or saline was administered into the left hindpaw. Withdrawal responses to mechanical and heat stimulation and oedema levels were evaluated at 3, 6 and 24 h post-carrageenan injection. 3. The results showed that the inflammatory effect of 1% carrageenan peaked after 6 h with bilateral decreases in withdrawal latencies and ipsilateral oedema formation. 4. Contralateral treatment with 0.01, 0.05, 0.3 and 2 mg of U-50,488H attenuated nociceptive reflexes to mechanical stimulation on the inflamed side at 6 h. The anti-nociceptive effect of contralateral treatment was dose-dependent at 3 and 24 h. The hindpaw withdrawal latencies to heat stimulation were prolonged at 3 and 24 h after contralateral treatment with 0.3 mg U-50,488H. No effect on inflammatory oedema formation was observed, except for a decrease at 3 h after treatment with 2 mg of U-50,488H. 5. Sciatic nerve denervation on the contralateral side abolished the anti-nociceptive effects of U-50,488H (0.3 and 2 mg). In contrast, contralateral injection of 1 mg morphine prolonged paw latencies in denervated rats. 6. Both co-administration of the peripherally selective opioid antagonist naloxone methiodide with 0.3 mg U-50,488H, and alternatively, systemic administration of 0.3 mg U-50,488H reversed the anti-nociceptive effects induced by contralateral injection of U-50,488H. 7. Taken together, our findings indicate that the contralateral administration of U-50,488H attenuates nociceptive behaviour resulting from acute inflammation. The effect is mediated via peripheral neuronal kappa-opioid receptors and, possibly, spinal cord mechanisms, suggesting a new treatment approach for acute inflammatory conditions.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/administration & dosage
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/antagonists & inhibitors
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology
- Acute Disease
- Analgesics, Opioid/administration & dosage
- Analgesics, Opioid/pharmacology
- Animals
- Behavior, Animal/drug effects
- Denervation
- Hindlimb/pathology
- Hot Temperature
- Inflammation/chemically induced
- Inflammation/complications
- Inflammation/pathology
- Male
- Naloxone/analogs & derivatives
- Naloxone/pharmacology
- Pain/drug therapy
- Pain/etiology
- Pain Measurement
- Physical Stimulation
- Quaternary Ammonium Compounds
- Rats
- Rats, Sprague-Dawley
- Receptors, Opioid, kappa/agonists
- Sciatic Nerve
Collapse
Affiliation(s)
- I Bileviciute-Ljungar
- Department of Physiology and Pharmacology, Karolinska Institutet, 171 77 Stockholm, Sweden.
| | | |
Collapse
|
9
|
Abstract
In the present study, we found that complement C3a exerted central effects after intracerebroventricular administration in mice. At doses of 3 and 10 pmol/mouse, the peptide showed an antagonistic effect on analgesia induced by morphine and U-50488H, known to be mu- and kappa-opioid receptor agonists, respectively. Moreover, complement C3a improved scopolamine- and ischemia-induced amnesia at a dose of 10 pmol/mouse. Anti-analgesia was not observed by C3a des-Arg at 10 pmol/mouse. The present findings suggest that complement C3a may act as a peptide with anti-opioid activity in the central nervous system.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/administration & dosage
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/antagonists & inhibitors
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology
- Analgesics/administration & dosage
- Analgesics/pharmacology
- Animals
- Avoidance Learning/drug effects
- Cerebral Ventricles/drug effects
- Cerebral Ventricles/physiology
- Complement C3a/administration & dosage
- Complement C3a/pharmacology
- Dose-Response Relationship, Drug
- Electroshock
- Humans
- Injections, Intraventricular
- Ischemia/physiopathology
- Male
- Mice
- Mice, Inbred Strains
- Morphine/administration & dosage
- Morphine/antagonists & inhibitors
- Morphine/pharmacology
- Oligopeptides/administration & dosage
- Oligopeptides/pharmacology
- Pain/physiopathology
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, kappa/agonists
- Receptors, Opioid, mu/agonists
Collapse
Affiliation(s)
- Y Jinsmaa
- Research Institute for Food Science, Kyoto University, Uji, Japan
| | | | | | | |
Collapse
|
10
|
Suh H, Song D, Huh S, Kim YH. Differential potentiative effects of glutamate receptor antagonists in the production of antinociception induced by opioids administered intrathecally in the mouse. Brain Res Bull 2000; 52:143-50. [PMID: 10808085 DOI: 10.1016/s0361-9230(00)00250-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The effect of (+/-)-5-methyl-10,11-dihydro-5H-dibenzo(a,d) cyclohepten-5, 10-imine maleate (MK-801) or 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) injected intrathecally (i.t.) on the inhibition of the tail-flick response induced by morphine, D-Ala(2)-NmePhe(4)-Gly-ol-enkephalin (DAMGO), beta-endorphin, D-Pen(2,5)-enkephalin (DPDPE), or ¿(trans-3, 4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl] benzeocetamide)¿ (U50, 488H) administered i.t. was studied in ICR mice. The i.t. injection of MK-801 (2 microg) or CNQX (1 microg) alone did not affect the basal tail-flick response. Morphine (0.2 microg), DAMGO (0.8 ng), beta-endorphin (0.1 microg), DPDPE (0.5 microg) or U50, 488H (6 microg) caused only slight inhibition of the tail-flick response. CNQX injected i.t., but not MK-801, enhanced the inhibition of the tail-flick response induced by i.t. administered morphine, DAMGO, DPDPE or U50, 488H. However, CNQX or MK-801 injected i.t. was not effective in enhancing the inhibition of the tail-flick response induced by beta-endorphin administered i.t. The potentiating effect of CNQX on tail-flick inhibition induced by morphine, DAMGO, DPDPE or U50, 488H was blocked by naloxone (from 1 to 20 microg), yohimbine (from 1 to 20 microg) or methysergide (from 1 to 20 microg) injected i.t. in a dose-dependent manner. Our results suggest that the blockade of AMPA/kainate receptors located in the spinal cord appears to be involved in enhancing the inhibition of the tail-flick response induced by stimulation of spinal mu-, delta-, and kappa-opioid receptors. Furthermore, this potentiating action may be mediated by spinal noradrenergic and serotonergic receptors. However, N-methyl-D-aspartate receptors may not be involved in modulating the inhibition of the tail-flick response induced by various opioids administered spinally.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/antagonists & inhibitors
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology
- 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage
- 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology
- Analgesics, Opioid/pharmacology
- Animals
- Dizocilpine Maleate/administration & dosage
- Dizocilpine Maleate/pharmacology
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-/antagonists & inhibitors
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-/pharmacology
- Enkephalin, D-Penicillamine (2,5)-/antagonists & inhibitors
- Enkephalin, D-Penicillamine (2,5)-/pharmacology
- Excitatory Amino Acid Antagonists/pharmacology
- Injections, Spinal
- Male
- Mice
- Mice, Inbred ICR
- Pain/physiopathology
- Pain/prevention & control
- Spinal Cord/drug effects
- Spinal Cord/physiology
- Time Factors
- beta-Endorphin/pharmacology
Collapse
Affiliation(s)
- H Suh
- Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University, Chunchon, South Korea.
| | | | | | | |
Collapse
|
11
|
Ko MC, Butelman ER, Woods JH. Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys. J Pharmacol Exp Ther 1999; 289:378-85. [PMID: 10087027 PMCID: PMC2865196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023] Open
Abstract
8-Methyl-N-vanillyl-6-nonenamide (capsaicin) was locally applied in the tail of rhesus monkeys to evoke a nociceptive response, thermal allodynia, which was manifested as reduced tail-withdrawal latencies in normally innocuous 46 degrees C water. Coadministration of three kappa opioid ligands, U50,488 (3.2-100 microgram), bremazocine (0.1-3.2 microgram), and dynorphin A(1-13) (3.2-100 microgram), with capsaicin in the tail dose-dependently inhibited capsaicin-induced allodynia. This local antinociception was antagonized by a small dose of an opioid antagonist, quadazocine; (0.32 mg), applied in the tail; however, this dose of quadazocine injected s.c. in the back did not antagonize local U50,488. Comparing the relative potency of either agonist or antagonist after local and systemic administration confirmed that the site of action of locally applied kappa opioid agonists is in the tail. In addition, local nor-binaltorphimine (0.32 mg) and oxilorphan (0.1-10 microgram) antagonist studies raised the possibility of kappa opioid receptor subtypes in the periphery, which indicated that U50,488 produced local antinociception by acting on kappa1 receptors, but bremazocine acted probably on non-kappa1 receptors. These results provide functional evidence that activation of peripheral kappa opioid receptors can diminish capsaicin-induced allodynia in primates. This experimental pain model is a useful tool for evaluating peripherally antinociceptive actions of kappa agonists without central side effects and suggests new approaches for opioid pain management.
Collapse
Affiliation(s)
- M C Ko
- Departments of Pharmacology and Psychology, University of Michigan, Ann Arbor, USA.
| | | | | |
Collapse
|
12
|
Zhu CB, Zhang XL, Xu SF, Cao XD, Wu GC, Li MY, Cui DF, Qi ZW. Antagonistic effect of orphanin FQ on opioid analgesia in rat. Zhongguo Yao Li Xue Bao 1998; 19:10-4. [PMID: 10375749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
AIM To study the effect of orphanin FQ (OFQ), a newly discovered heptadecapeptide, on nociception and opioid analgesia. METHODS The intracerebroventricular (i.c.v.) and intrathecal (i.t.h.) injections were used to give the drugs. The tail-flick model of rats were used to test the pain threshold. RESULTS OFQ (i.c.v. or i.t.h.) 0.1 microgram had no effect on nociception but 0.5-10 micrograms induces hyper-reaction of rat to noxious electric stimulus; the decapeptide (OFQ1-10 i.c.v.), a fragment of the OFQ, did not affect the pain reaction of rats. Fentanyl (1 microgram, i.c.v. or i.t.h.), a selective mu-receptor agonist, DSLET (5 micrograms, i.c.v. or i.t.h.), a selective delta-receptor agonist, or U50488H (1 microgram, i.t.h.), a kappa-receptor agonist, induced an increase in pain threshold, when OFQ (0.1 or 1 microgram) was added together with one of them (except for the ith injection of DSLET), the increase of pain threshold was reduced obviously. CONCLUSION OFQ induces hyperalgesia and antagonizes opioid analgesia mediated by mu- and delta-receptors in the brain and by mu- and kappa- but not delta-receptors in the spinal cord of rats.
Collapse
Affiliation(s)
- C B Zhu
- State Key Laboratory of Medical Neurobiology, Department of Neurobiology, Shanghai Medical University, China
| | | | | | | | | | | | | | | |
Collapse
|